122 related articles for article (PubMed ID: 23578235)
1. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Hossain D; Bostwick DG
BJU Int; 2013 May; 111(5):834-5. PubMed ID: 23578235
[No Abstract] [Full Text] [Related]
2. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
4. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Smit FP; Salagierski M; Jannink S; Schalken JA
BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R; Latour M; Toubaji A; Haffner M; Isaacs WB; A Platz E; Meeker AK; Demarzo AM; Epstein JI; Netto GJ
Mod Pathol; 2009 Nov; 22(11):1415-22. PubMed ID: 19734849
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].
Allina DO; Kekeeva TV; Moskvina LV; Shikeeva AA; Andreeva YY; Zavalishina LE; Frank GA
Arkh Patol; 2015; 77(5):36-42. PubMed ID: 26978019
[TBL] [Abstract][Full Text] [Related]
8. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
[TBL] [Abstract][Full Text] [Related]
9. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.
Soller MJ; Isaksson M; Elfving P; Soller W; Lundgren R; Panagopoulos I
Genes Chromosomes Cancer; 2006 Jul; 45(7):717-9. PubMed ID: 16575875
[No Abstract] [Full Text] [Related]
11. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
12. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
14. Medicine. Fused genes may help explain the origins of prostate cancer.
Marx J
Science; 2005 Oct; 310(5748):603. PubMed ID: 16254158
[No Abstract] [Full Text] [Related]
15. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
[TBL] [Abstract][Full Text] [Related]
16. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
17. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
19. ERG protein expression as a biomarker of prostate cancer.
Falzarano SM; Magi-Galluzzi C
Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
[TBL] [Abstract][Full Text] [Related]
20. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
